• Constantinos Chrysostomou
  • Traci M. Kazmerski

β-blockers have become an essential component of pharmacological therapy for adults with chronic congestive heart failure (CHF). They have been shown to decrease morbidity and mortality in several randomized controlled studies. Nonetheless, one has to take into consideration some of the differences that exist between pediatric and adult heart failure when considering β-blockers. Heart failure in adults is most often a problem caused by left ventricular (LV) systolic dysfunction that occurs with damage from ischemia, hypertension, or older age. Pediatric heart failure can be secondary to primary systolic dysfunction that is either acquired or congenital but most commonly is caused by congenital structural defects. Patients born with single ventricle defects, and especially those with a single right ventricle, seem to be particularly prone to ventricular dysfunction over time. Despite these differences in the etiology of heart failure, there is substantial evidence that infants and children have alterations in their neurohormonal axes that are similar to adults.


Severe Heart Failure Chronic Congestive Heart Failure Abrupt Withdrawal Dihydropyridine Calcium Channel Blocker Carvedilol Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Ross RD, Daniels SR, Schwartz DC, et al. (1987). Plasma norepinephrine levels in infants and children with congestive heart failure. Am J Cardiol 59(8): 911–914.PubMedCrossRefGoogle Scholar
  2. 2.
    Saltissi S, Mushahwar S. (1995). The management of acute myocardial infarction. Postgrad Med J 71(839): 534–541.PubMedCrossRefGoogle Scholar
  3. 3.
    Falkner B, Lowenthal D, et al. (1982). The pharmacodynamic effectiveness of metoprolol in adolescent hypertension. Pediatr Pharmacol (New York) 2(1): 49–55.Google Scholar
  4. 4.
    Torp-Pedersen C, Poole-Wilson P, et al. (2005). Effects of metoprolol and carvedilol on cause-specific mortality and morbidity in patients with chronic heart failure—COMET. Am Heart J 149(2): 370–376.PubMedCrossRefGoogle Scholar
  5. 5.
    Stroe A, Gheorghiade M. (2004). Carvedilol: beta-blockade and beyond. Rev Cardiovasc Med 5(Supp 1): S18–27.PubMedGoogle Scholar
  6. 6.
    Bristow MR. (2000). B1-adrenergic receptor blockade in chronic heart failure. Circulation 101(5): 558–569.PubMedGoogle Scholar
  7. 7.
    Lubbe WF, Podzuweit T, Opie LH. (1992). Potential arrhythmogenic role of cyclic adenosine monophosphate (AMP) and cytosolic calcium overload: implications of prophylactic effects of beta-blockers in myocardial infarction and proarrhythmic effect of phosphodiesterase inhibitors. J Am Coll Cardiol 19(7): 1622–1633.PubMedGoogle Scholar
  8. 8.
    Pogwizd SM, Schlotthauer K, Li L, Yuan W, Bers DM. (2001). Arrhythmogenesis and contractile dysfunction in heart failure: Roles of sodium-calcium exchange, inward rectifier potassium current, and residual beta-adrenergic responsiveness. Circ Res 88: 1159–1167.PubMedCrossRefGoogle Scholar
  9. 9.
    RESOLVD Investigators. (2000). Effects of Metoprolol CR in patients with ischemic and dilated cardiomyopathy. The randomized evaluation of strategies for left ventricular dysfunction pilot study.Circulation 101(4): 378–384.Google Scholar
  10. 10.
    MERIT-HF Study group. (1999). Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomized trial in congestive heart failure (MERIT-HF). Lancet 353(9169): 2001–2007.Google Scholar
  11. 11.
    Shaddy RE, Olsen SL, Bristow MR, et al. (1995). Efficacy and safety of metoprolol in the treatment of doxorubicin-induced cardiomyopathy in pediatric patients. Am Heart J 129(1): 197–199.PubMedCrossRefGoogle Scholar
  12. 12.
    Shaddy RE, Tani LY, Gidding SS, et al. (1999). Beta blocker treatment of dilated cardiomyopathy with congestive heart failure in children: a multi-institutional experience. J Heart Lung Transplant 18(3): 269–274.PubMedCrossRefGoogle Scholar
  13. 13.
    Ishikawa Y, Bach JR, Minami R. (1999). Cardioprotection for Duchenne’s muscular dystrophy. Am Heart J 137(5): 895–902.PubMedCrossRefGoogle Scholar
  14. 14.
    Lennard MS, Silas JH, Freestone S, et al. (1982) Oxidation phenotype—a major determinant of metoprolol metabolism and response. N Engl J Med 307: 1558–1560.PubMedCrossRefGoogle Scholar
  15. 15.
    CAPRICORN Investigators. Effects of carvedilol on outcome after myocardial infarction in patients with left ventricular dysfunction: the CAPRICORN randomized trial. Lancet 357(9266): 1385–1390.Google Scholar
  16. 16.
    Bruns LA, Chrisant MK, Lamour JM, et al. (2001). Carvedilol as therapy in pediatric heart failure: an initial multicenter experience. J Pediatr 138(4): 505–511.PubMedCrossRefGoogle Scholar
  17. 17.
    Blume ED, Canter CE, Spicer R, et al. (2006). Prospective single-arm protocol of carvedilol in children with ventricular dysfunction. Pediatr Cardiol 27(3): 336–342.PubMedCrossRefGoogle Scholar
  18. 18.
    Moser M, Frishman W. (1998). Results of therapy with carvedilol, a beta-blocker vasodilator with antioxidant properties, in hypertensive patients. Am J Hypertens 11(1 Pt 2): 15S–22S.Google Scholar
  19. 19.
    Laer S, Mir T, et al. (2002). Carvedilol therapy in pediatric patients with congestive heart failure: a study investigating clinical and pharmacokinetic parameters. Am Heart J 143(5): 916–922.PubMedCrossRefGoogle Scholar
  20. 20.
    Neugebauer G, Gabor M, Reiff K. (1988). Pharmacokinetics and bioavailability of carvedilol in patients with liver cirrhosis. Drugs 36(suppl 6):148–154.CrossRefGoogle Scholar
  21. 21.
    Morgan, T. (1994). Clinical pharmacokinetics and pharmacodynamics of carvedilol. Clin Pharmacokinet 26(5): 335–346.PubMedCrossRefGoogle Scholar
  22. 22.
    Buchhorn R, Hulpke-Wette M, Hilgers R, et al. (2001). Propranolol treatment of congestive heart failure in infants with congenital heart disease: The CHF-PRO-INFANT Trial Int J Cardiol 79(2–3):167–173.Google Scholar

Copyright information

© Springer-Verlag London Limited 2008

Authors and Affiliations

  • Constantinos Chrysostomou
    • 1
  • Traci M. Kazmerski
    • 2
  1. 1.Department of Pediatrics and Critical CareChildren's Hospital of PittsburghPittsburghUSA
  2. 2.Cardiac Intensive Care UnitChildren's Hospital of PittsburghPittsburghUSA

Personalised recommendations